ESR1 and breast cancer: The porcupine O-acyltransferase (PORCN) inhibitors LGK-974 or IWP-2, which prevent Wnt ligand secretion, rescued the increased proliferation of INPP4B-overexpressing ER+ breast cancer cells [25].